Functional Genomic Screening Independently Identifies CUL3 as a Mediator of Vemurafenib Resistance via Src-Rac1 Signaling Axis

Abstract excerpt

Patients with malignant melanoma have a five‐year survival rate of only 15–20% once the tumor has metastasized to distant tissues. While MAP kinase pathway inhibitors (MAPKi) are initially effective for the majority of patients with melanoma harboring BRAFV600E mutation, over 90% of patients relapse within two years. Thus, there is a critical need for understanding MAPKi resistance mechanisms. In this manuscript,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Mechanisms and Therapy
• Share to Melanoma and MAPK Pathways
• Share to PI3K/AKT/mTOR signaling in cancer